Request Demo
Last update 02 Jul 2026
Nilvanstomig
Last update 02 Jul 2026
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms ZG-005, ZG005 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 453608435
Source: *****
Sequence Code 453608436
Source: *****
Related
15
Clinical Trials associated with NilvanstomigNCT07099547
A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Platinum-Based Chemotherapy as First-Line Treatment in Participants With Advanced Biliary Tract Carcinoma
NCT07038096
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
NCT07080216
A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
100 Clinical Results associated with Nilvanstomig
Login to view more data
100 Translational Medicine associated with Nilvanstomig
Login to view more data
100 Patents (Medical) associated with Nilvanstomig
Login to view more data
100 Deals associated with Nilvanstomig
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Biliary Tract Neoplasms | Phase 2 | China | 02 Dec 2025 | |
| Advanced biliary tract cancer | Phase 2 | China | 11 Nov 2025 | |
| Gallbladder Neoplasms | Phase 2 | China | 11 Nov 2025 | |
| Small Cell Lung Cancer | Phase 2 | China | 23 Sep 2025 | |
| Advanced Lung Small Cell Carcinoma | Phase 2 | China | 04 Sep 2025 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | China | 29 May 2025 | |
| Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 08 May 2025 | |
| Recurrent Lymphoma | Phase 2 | China | 28 Apr 2025 | |
| Refractory Lymphoma | Phase 2 | China | 28 Apr 2025 | |
| Classical Hodgkin's Lymphoma | Phase 2 | China | 21 Apr 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | Advanced Hepatocellular Carcinoma First line | 95 | byjoecjabd(ajyfykttwq) = nngicbsyvk gmgeklfnfx (ayzoyxqpis ) View more | Positive | 29 May 2026 | ||
byjoecjabd(ajyfykttwq) = qauejqmnvy gmgeklfnfx (ayzoyxqpis ) View more | |||||||
| - | Advanced Cervical Carcinoma First line | 60 | kinubrnict(sqibudazaf) = vknkhcunoa jifxwqugau (twlyhflcmd ) View more | Positive | 31 Oct 2025 | ||
rvxssumrtl(feroggqqls) = awzieanqri uzthqtmbfe (nvwtbskzdi ) View more | |||||||
Phase 1 | 21 | gyxkvjrksk(elaexbsqqk) = fkhsqllpbj ggjdmzndxt (flcqsivmkz ) View more | Positive | 31 Oct 2025 | |||
Phase 1/2 | Advanced Neuroendocrine Carcinoma First line | 39 | wsibrbdjtu(uviqroxwgr) = No dose-limiting toxicities (DLT) were observed in part 1 cwnzmaovjf (otghcankml ) View more | Positive | 17 Oct 2025 | ||
Phase 1/2 | Advanced Neuroendocrine Carcinoma First line | 84 | flziqpmbig(xyilzsdudx) = llfbeiocye kkndtgivwc (mloiuxbssc ) View more | Positive | 11 Sep 2025 | ||
flziqpmbig(xyilzsdudx) = ukelkiojjg kkndtgivwc (mloiuxbssc ) View more | |||||||
Phase 1/2 | Advanced Cervical Carcinoma Second line | 55 | przlhnkuaf(hffhmryjrz) = vwrkucgqew rpxtjvschl (fnzhkailgg ) View more | Positive | 30 May 2025 | ||
pamjupeiej(cdlyprxnlw) = spbzqnfzht uuysxqfgje (eiewznlkwb ) View more | |||||||
Phase 1/2 | Advanced Cervical Carcinoma First line | 41 | xgjixughje(eixwxvlnxv) = 1 SAE of bilateral lung pneumonia in the 10 mg/kg group was assessed related to ZG005 by the investigator clfwxnnffw (vpkbasbxsb ) | Positive | 30 May 2025 | ||
CTR20220021 (NEWS) Manual  | Phase 1/2 | 46 | tqqjoylbnd(ufsalqlrrl) = jeotvrlhvy gzplcmppnk (hwbeesjsen ) View more | Positive | 25 Sep 2024 | ||
(20 mg/kg) | tqqjoylbnd(ufsalqlrrl) = tlufsjlsgy gzplcmppnk (hwbeesjsen ) View more | ||||||
Not Applicable | Advanced Hepatocellular Carcinoma First line | 10 | cnllzuixpu(jqpxeiftfx) = pmxwnzooan gluufoasrn (yhdncbjbig ) View more | Positive | 25 Sep 2024 | ||
CTR20220021 (ASCO2024) Manual | Phase 1 | 57 | tbjtymzvfo(mtqumohymc) = xqswwpueqw thuniyyscu (rdxjmxxcfz ) View more | Positive | 24 May 2024 | ||
(cervical cancer) | tbjtymzvfo(mtqumohymc) = isoxvlznje thuniyyscu (rdxjmxxcfz ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free